14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZBIO vs VTYX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Zenas BioPharma, Inc. (ZBIO) on higher Unified Composite conviction (50.4/100 HOLD vs. 49.4/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality), while ZBIO wins 3–1 across the 6-pillar growth and valuation breakdown. ZBIO trades at $27.93 (N/M Forward P/E, -2747.5% operating margin) versus VTYX at $14.00 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: VTYX earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. ZBIO 49.4/100 HOLD) and 2.07β · 2% Vol risk profile, whereas ZBIO leads top-line expansion (-100.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZBIO vs VTYX. Trailing 12-month operating profitability (ZBIO -2747.5% vs VTYX 0.0%) and valuation multiples (ZBIO N/M vs VTYX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ZBIO vs VTYX Key Questions & Quantitative Answers
As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Zenas BioPharma, Inc. (ZBIO) on higher Unified Composite conviction (50.4/100 HOLD vs. 49.4/100 HOLD) after splitting the core matrix 6–1 (led by Profitability & Quality), while ZBIO wins 3–1 across the 6-pillar growth and valuation breakdown. ZBIO trades at $27.93 (N/M Forward P/E, -2747.5% operating margin) versus VTYX at $14.00 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: VTYX earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. ZBIO 49.4/100 HOLD) and 2.07β · 2% Vol risk profile, whereas ZBIO leads top-line expansion (-100.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile VTYX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ZBIO leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with VTYX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ZBIO generates $11M in USD-normalized revenue versus N/A for VTYX. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTYX.
ZBIO and VTYX trade at balanced relative valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus VTYX (-45.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ZBIO carries 95.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.